» Articles » PMID: 39133931

Unbalanced MYC Break-apart FISH Patterns Indicate the Presence of a MYC Rearrangement in HGBCL-DH-BCL2

Abstract

Fluorescence in situ hybridization (FISH) using break-apart probes is recommended for identifying high-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2). Unbalanced MYC break-apart patterns, in which the red or green signal is lost, are commonly reported as an equivocal result by clinical laboratories. In a cohort of 297 HGBCL-DH-BCL2, 13% of tumors had unbalanced MYC break-apart patterns with loss of red (LR; 2%) or loss of green (LG; 11%) signal. To determine the significance of these patterns, MYC rearrangements were characterized by sequencing in 130 HGBCL-DH-BCL2, including 3 LR and 14 LG tumors. A MYC rearrangement was identified for 71% of tumors with LR or LG patterns, with the majority involving immunoglobulin loci or other recurrent MYC rearrangement partners. The architecture of these rearrangements consistently preserved the rearranged MYC allele, with the MYC gene predicted to be on the derivative chromosome containing the signal that is still present in nearly all cases. MYC protein expression, MYC messenger RNA expression, and the proportion of tumors expressing the dark-zone signature was not significantly different between balanced and unbalanced groups. These results support a recommendation that unbalanced MYC break-apart FISH patterns be reported as positive for MYC rearrangement in the context of diagnosing HGBCL-DH-BCL2.

Citing Articles

High-grade B-cell lymphoma, not otherwise specified, presenting as primary peritoneal lymphomatosis and successfully treated with dose-adjusted EPOCH-R.

Fujimi A, Nagamachi Y, Yamauchi N, Onoyama N, Hayasaka N, Matsuno T J Clin Exp Hematop. 2024; 64(1):37-44.

PMID: 38281744 PMC: 11079986. DOI: 10.3960/jslrt.23044.


Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis.

Gagnon M, Penheiter A, Harris F, Sadeghian D, Johnson S, Karagouga G Blood Cancer J. 2023; 13(1):190.

PMID: 38114462 PMC: 10730864. DOI: 10.1038/s41408-023-00967-8.

References
1.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

2.
Morin R, Mungall K, Pleasance E, Mungall A, Goya R, Huff R . Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013; 122(7):1256-65. PMC: 3744992. DOI: 10.1182/blood-2013-02-483727. View

3.
Hilton L, Ngu H, Collinge B, Dreval K, Ben-Neriah S, Rushton C . Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2023; 41(25):4164-4177. PMC: 10852398. DOI: 10.1200/JCO.23.00570. View

4.
Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Kallberg M . Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2015; 32(8):1220-2. DOI: 10.1093/bioinformatics/btv710. View

5.
Scott D, King R, Staiger A, Ben-Neriah S, Jiang A, Horn H . High-grade B-cell lymphoma with and and/or rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018; 131(18):2060-2064. PMC: 6158813. DOI: 10.1182/blood-2017-12-820605. View